In eight patients with CRC with repeat liquid biopsies, one additional mutation in the mitogen-activated protein kinase/extracellular signal–regulated kinases (MAPK/ERK or RAF/MEK/ERK) pathway was detected in addition to KRASG12C, consistent with acquired resistance to monoclonal antibody therapy. The gene discussed is WNK2; the disease is colorectal carcinoma.